Evidence map›Paper›PMID 38234336›Full record

ArticleAME case reports2024

Calcitonin-secreting neuroendocrine tumor of the larynx, a diagnostic challenge of a rare neoplasm: a case report and literature review.

Daria Maria Filippini, Andi Abeshi, Nastassja Tober, Paola Valeria Marchese, Elisa Andrini, Giuseppe Lamberti, Roberto Agosti, Giulia Molinari, Matteo Fermi, Livio Presutti

Open access · diamondAbstract readCase Reports
In one paragraph

Article in AME case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Daria Maria Filippini *Division of Medical Oncology, Sant'Orsola-Malpighi University Hospital, Bologna, Italy.
Andi Abeshi *Department of Otolaryngology - Head and Neck Surgery, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Nastassja ToberDivision of Medical Oncology, Sant'Orsola-Malpighi University Hospital, Bologna, Italy.
Paola Valeria MarcheseDivision of Medical Oncology, Sant'Orsola-Malpighi University Hospital, Bologna, Italy.
Elisa AndriniDivision of Medical Oncology, Sant'Orsola-Malpighi University Hospital, Bologna, Italy.
Giuseppe LambertiDivision of Medical Oncology, Sant'Orsola-Malpighi University Hospital, Bologna, Italy.
Roberto AgostiPathology Department, Sant'Orsola-Malpighi University Hospital, Bologna, Italy.
Giulia MolinariDepartment of Medical and Surgical Sciences (DIMEC), Sant'Orsola-Malpighi University Hospital, Bologna, Italy.
Matteo FermiDepartment of Medical and Surgical Sciences (DIMEC), Sant'Orsola-Malpighi University Hospital, Bologna, Italy.
Livio PresuttiDepartment of Medical and Surgical Sciences (DIMEC), Sant'Orsola-Malpighi University Hospital, Bologna, Italy.
Policlinico S.Orsola-Malpighi · ITAzienda USL di Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Laryngeal neuroendocrine tumors (NETs) represent less than 1% of all malignancies originating from the larynx and available data are limited on case reports. Calcitonin secreting laryngeal NETs are extremely rare and serial dosing of calcitonin in these patients might reveal early relapse or persistence. Case Description: We report the case of a 71-year-old woman with persistent pharyngodynia who underwent surgery for an initial diagnosis of small cell undifferentiated neuroendocrine carcinoma (SCUNC) of the larynx (on the epiglottis extended to the left glosso-epiglottic vallecula). The immunohistochemical profile showed the presence of synaptophysin, neuron-specific enolase (NSE), chromogranin A, pan-cytokeratin, including cytokeratin AE1-AE2, and focally calcitonin. The circulating NSE was 13.4 microg/L (normal level <12.5 microg/L) and the basal serum level of calcitonin was 237 pg/mL (normal level <11.5 pg/mL). The patient was started on first-line carboplatin-etoposide chemotherapy because of early relapse to an axillary lymph node. After 4 cycles of treatment, a radiological stability and metabolic response were demonstrated together with a drastic decrease of circulating serum level of calcitonin (from 237 to 57.9 pg/mL). During the follow up, locoregional relapse of disease occurred, associated with an increase of serum calcitonin (89.3 pg/mL). Disease further progressed on and rechallenge with platinum-etoposide chemotherapy was administered, during which clinical progression was confirmed. Due to the lack of response, a revision of the histology was performed and concluded for a definitive diagnosis of moderately differentiated G2 NET, with a Ki-67 index of 22.6%. Conclusions: This is the eighth case report of laryngeal NET, highlighting the challenge in pathological differential diagnosis and therapeutic strategies. The association with elevated serum calcitonin and the trend of this parameter during clinical progression suggest a role of this marker in the diagnosis and early identification of recurrent laryngeal NETs.

Indexed as

calcitonincase reportLarynxneuroendocrinerare cancer

Identifiers

PMID38234336
PMCPMC10789897
OpenAlexW4390668951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.